A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma

Molecular Therapy

Volumn 18, Issue 8, 2010, Pages 1559-1567

  Peruzzi, Daniela ^a,c   Gavazza, Alessandra ^b   Mesiti, Giuseppe ^a   Lubas, George ^b   Scarselli, Elisa ^a   Conforti, Antonella ^a   Bendtsen, Claus ^a   Ciliberto, Gennaro ^a,d   La Monica, Nicola ^a,e   Aurisicchio, Luigi ^a,f  

^a IRBM   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e HYBRIDON INC   (United States)

^f Grande Ospedale Metropolitano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; MELPHALAN; PLASMID DNA; PREDNISONE; TELOMERASE REVERSE TRANSCRIPTASE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; DRUG TARGETING; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS;

EID: 77955172418     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.104     Document Type: Article

References (50)

1. Meyerson, M, Counter, CM, Eaton, EN, Ellisen, LW, Steiner, P, Caddle, SD et al. (1997). hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
2. Nakamura, TM, Morin, GB, Chapman, KB, Weinrich, SL, Andrews, WH, Lingner, J et al. (1997). Telomerase catalytic subunit homologs from fssion yeast and human. Science 277: 955-959.
3. Kim, NW, Piatyszek, MA, Prowse, KR, Harley, CB, West, MD, Ho, PL et al. (1994). Specifc association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
4. Vonderheide, RH (2007). Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov Med 7: 103-108.
5. Chen, DY, Vance, BA, Thompson, LB, Domchek, SM and Vonderheide, RH (2007). Differential lysis of tumors by polyclonal T cell lines and T cell clones specifc for hTERT. Cancer Biol Ther 6: 1991-1996.
6. Su, Z, Dannull, J, Yang, BK, Dahm, P, Coleman, D, Yancey, D et al. (2005). Telomerase mRNA-transfected dendritic cells stimulate antigen-specifc CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174: 3798-3807.
7. Domchek, SM, Recio, A, Mick, R, Clark, CE, Carpenter, EL, Fox, KR et al. (2007). Telomerase-specifc T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 67: 10546-10555.
8. Aurisicchio, L, Mennuni, C, Giannetti, P, Calvaruso, F, Nuzzo, M, Cipriani, B et al. (2007). Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 120: 2290-2300.
9. Babiuk, S, Baca-Estrada, ME, Foldvari, M, Storms, M, Rabussay, D, Widera, G et al. (2002). Electroporation improves the effcacy of DNA vaccines in large animals. Vaccine 20: 3399-3408.
10. Scheerlinck, J P, Karlis, J, Tjelle, TE, Presidente, PJ, Mathiesen, I and Newton, SE (2004). In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22: 1820-1825.
11. Zucchelli, S, Capone, S, Fattori, E, Folgori, A, Di Marco, A, Casimiro, D et al. (2000). Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 74: 11598-11607.
12. Shiver, JW, Fu, TM, Chen, L, Casimiro, DR, Davies, ME, Evans, RK et al. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodefciency-virus immunity. Nature 415: 331-335.
13. Casimiro, DR, Bett, AJ, Fu, TM, Davies, ME, Tang, A, Wilson, KA et al. (2004). Heterologous human immunodefciency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78: 11434-11438.
14. Yang, ZY, Wyatt, LS, Kong, WP, Moodie, Z, Moss, B and Nabel, GJ (2003). Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77: 799-803.
15. Uva, P, Aurisicchio, L, Watters, J, Loboda, A, Kulkarni, A, Castle, J et al. (2009). Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 10: 135.
16. Gavazza, A, Presciuttini, S, Barale, R, Lubas, G and Gugliucci, B (2001). Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. J Vet Intern Med 15: 190-195.
17. Bergman, PJ, McKnight, J, Novosad, A, Charney, S, Farrelly, J, Craft, D et al. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9: 1284-1290.
18. Bergman, PJ, Camps-Palau, MA, McKnight, JA, Leibman, NF, Craft, DM, Leung, C et al. (2006). Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24: 4582-4585.
19. Argyle, DJ and Nasir, L (2003). Telomerase: a potential diagnostic and therapeutic tool in canine oncology. Vet Pathol 40: 1-7.
20. Nasir, L (2008). Telomeres and telomerase: biological and clinical importance in dogs. Vet J 175: 155-163.
21. Nasir, L, Devlin, P, Mckevitt, T, Rutteman, G and Argyle, DJ (2001). Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 3: 351-359.
22. Yazawa, M, Okuda, M, Setoguchi, A, Iwabuchi, S, Nishimura, R, Sasaki, N et al. (2001). Telomere length and telomerase activity in canine mammary gland tumors. Am J Vet Res 62: 1539-1543.
23. Yazawa, M, Okuda, M, Setoguchi, A, Nishimura, R, Sasaki, N, Hasegawa, A et al. (1999). Measurement of telomerase activity in dog tumors. J Vet Med Sci 61: 1125-1129.
24. Angelopoulou, K, Zavlaris, M, Papaioannou, N and Vlemmas, I (2008). Canis familiaris telomerase reverse transcriptase undergoes alternative splicing. Mamm Genome 19: 647-653.
25. Nasir, L, Gault, E, Campbell, S, Veeramalai, M, Gilbert, D, McFarlane, R et al. (2004). Isolation and expression of the reverse transcriptase component of the Canis familiaris telomerase ribonucleoprotein (dogTERT). Gene 336: 105-113.
26. Lund, JR, Paoloni, M, Kurzman, I, Padilla, M and Argyle, DJ (2008). Inhibition of canine telomerase in vitro and in vivo using RNAi: further development of a natural canine model for telomerase-based cancer therapies. Vet J 177: 192-197.
27. Pang, LY and Argyle, DJ (2009). Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta 1792: 380-391.
28. Simon, D, Moreno, SN, Hirschberger, J, Moritz, A, Kohn, B, Neumann, S et al. (2008). Effcacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc 232: 879-885.
29. Gavazza, A, Sacchini, F, Lubas, G, Gugliucci, B and Valori, E (2009). Clinical, laboratory, diagnostic and prognostic aspects of canine lymphoma: a retrospective study. Comp Clin Path 18:291-299.
30. Hayes, HM, Tarone, RE, Cantor, KP, Jessen, CR, McCurnin, DM and Richardson, RC (1991). Case-control study of canine malignant lymphoma: positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 83: 1226-1231.
31. Vail, DM and Young, KM (2007). Hematopoietic tumors. In: Withrow, SJ and MacEven, EG (eds). Small Animal Clinical Oncology, 4th edn. Elsevier: St Louis, MO.
32. WHO (1980). TNM Classifcation of Tumors in Domestic Animals. WHO Proceedings, Geneva. pp. 46-54.
33. Fournel-Fleury, C, Magnol, JP, Bricaire, P, Marchal, T, Chabanne, L, Delverdier, A et al. (1997). Cytohistological and immunological classifcation of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J Comp Pathol 117: 35-59.
34. Willmann, M, Müllauer, L, Guija de Arespacochaga, A, Reifnger, M, Mosberger, I and Thalhammer, JG (2009). Pax5 immunostaining in paraffn-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B-and B-cell marker. Vet Immunol Immunopathol 128: 359-365.
35. Ponce, F, Magnol, JP, Ledieu, D, Marchal, T, Turinelli, V, Chalvet-Monfray, K et al. (2004). Prognostic signifcance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J 167: 158-166.
36. Yazawa, M, Okuda, M, Kanaya, N, Hong, SH, Takahashi, T, Ohashi, E et al. (2003). Molecular cloning of the canine telomerase reverse transcriptase gene and its expression in neoplastic and non-neoplastic cells. Am J Vet Res 64: 1395-1400. (Pubitemid 37407392)
37. Peruzzi, D, Mesiti, G, Ciliberto, G, La Monica, N and Aurisicchio, L (2010). Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 28: 1201-1208.
38. Dharmapuri, S, Peruzzi, D, Mennuni, C, Calvaruso, F, Giampaoli, S, Barbato, G et al. (2009). Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther 17: 1804-1813.
39. Inogès, S, Rodrìguez-Calvillo, M, Zabalegui, N, Lòpez-Dìaz de Cerio, A, Villanueva, H, Soria, E et al.; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group. (2006). Clinical beneft associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98: 1292-1301.
40. Bendandi, M (2009). Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 9: 675-681.
41. Mennuni, C, Ugel, S, Mori, F, Cipriani, B, Iezzi, M, Pannellini, T et al. (2008). Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 68: 9865-9874.
42. Breen, M and Modiano, JF (2008). Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Res 16: 145-154.
43. van der Most, RG, Currie, A, Robinson, BW and Lake, RA (2006). Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66: 601-604.
44. Bracci, L, Moschella, F, Sestili, P, La Sorsa, V, Valentini, M, Canini, I et al. (2007). Cyclophosphamide enhances the antitumor effcacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specifc tumor infltration. Clin Cancer Res 13(2 Pt 1): 644-653.
45. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648.
46. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
47. Nisticò, P, Capone, I, Palermo, B, Del Bello, D, Ferraresi, V, Moschella, F et al. (2009). Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 124: 130-139.
48. Kamstock, D, Elmslie, R, Thamm, D and Dow, S (2007). Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 56: 1299-1309.
49. van Meerten, T and Hagenbeek, A (2009). CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med 67: 251-259.
50. Facciabene, A, Aurisicchio, L and La Monica, N (2004). Baculovirus vectors elicit antigen-specifc immune responses in mice. J Virol 78: 8663-8672.